IL10 Secretion Endows Intestinal Human iNKT Cells with Regulatory Functions Towards Pathogenic T Lymphocytes.


Journal

Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676

Informations de publication

Date de publication:
08 Sep 2022
Historique:
pubmed: 1 4 2022
medline: 14 9 2022
entrez: 31 3 2022
Statut: ppublish

Résumé

Invariant natural killer T [iNKT] cells perform pleiotropic functions in different tissues by secreting a vast array of pro-inflammatory and cytotoxic molecules. However, the presence and function of human intestinal iNKT cells capable of secreting immunomodulatory molecules such as IL-10 has never been reported so far. Here we describe for the first time the presence of IL10-producing iNKT cells [NKT10 cells] in the intestinal lamina propria of healthy individuals and of Crohn's disease [CD] patients. Frequency and phenotype of NKT10 cells were analysed ex vivo from intestinal specimens of Crohn's disease [n = 17] and controls [n = 7]. Stable CD-derived intestinal NKT10 cell lines were used to perform in vitro suppression assays and co-cultures with patient-derived mucosa-associated microbiota. Experimental colitis models were performed by adoptive cell transfer of splenic naïve CD4+ T cells in the presence or absence of IL10-sufficient or -deficient iNKT cells. In vivo induction of NKT10 cells was performed by administration of short chain fatty acids [SCFA] by oral gavage. Patient-derived intestinal NKT10 cells demonstrated suppressive capabilities towards pathogenic CD4+ T cells. The presence of increased proportions of mucosal NKT10 cells associated with better clinical outcomes in CD patients. Moreover, an intestinal microbial community enriched in SCFA-producing bacteria sustained the production of IL10 by iNKT cells. Finally, IL10-deficient iNKT cells failed to control the pathogenic activity of adoptively transferred CD4+ T cells in an experimental colitis model. These results describe an unprecedentd IL10-mediated immunoregulatory role of intestinal iNKT cells in controlling the pathogenic functions of mucosal T helper subsets and in maintaining the intestinal immune homeostasis.

Sections du résumé

BACKGROUND AND AIMS OBJECTIVE
Invariant natural killer T [iNKT] cells perform pleiotropic functions in different tissues by secreting a vast array of pro-inflammatory and cytotoxic molecules. However, the presence and function of human intestinal iNKT cells capable of secreting immunomodulatory molecules such as IL-10 has never been reported so far. Here we describe for the first time the presence of IL10-producing iNKT cells [NKT10 cells] in the intestinal lamina propria of healthy individuals and of Crohn's disease [CD] patients.
METHODS METHODS
Frequency and phenotype of NKT10 cells were analysed ex vivo from intestinal specimens of Crohn's disease [n = 17] and controls [n = 7]. Stable CD-derived intestinal NKT10 cell lines were used to perform in vitro suppression assays and co-cultures with patient-derived mucosa-associated microbiota. Experimental colitis models were performed by adoptive cell transfer of splenic naïve CD4+ T cells in the presence or absence of IL10-sufficient or -deficient iNKT cells. In vivo induction of NKT10 cells was performed by administration of short chain fatty acids [SCFA] by oral gavage.
RESULTS RESULTS
Patient-derived intestinal NKT10 cells demonstrated suppressive capabilities towards pathogenic CD4+ T cells. The presence of increased proportions of mucosal NKT10 cells associated with better clinical outcomes in CD patients. Moreover, an intestinal microbial community enriched in SCFA-producing bacteria sustained the production of IL10 by iNKT cells. Finally, IL10-deficient iNKT cells failed to control the pathogenic activity of adoptively transferred CD4+ T cells in an experimental colitis model.
CONCLUSIONS CONCLUSIONS
These results describe an unprecedentd IL10-mediated immunoregulatory role of intestinal iNKT cells in controlling the pathogenic functions of mucosal T helper subsets and in maintaining the intestinal immune homeostasis.

Identifiants

pubmed: 35358301
pii: 6561819
doi: 10.1093/ecco-jcc/jjac049
pmc: PMC9455792
doi:

Substances chimiques

IL10 protein, human 0
Interleukin-10 130068-27-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1461-1474

Subventions

Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 14378
Organisme : Italy's Ministry of Health
ID : GR-2016-0236174

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation.

Références

Immunity. 2008 Apr;28(4):546-58
pubmed: 18387831
Front Med (Lausanne). 2018 Feb 07;5:21
pubmed: 29468162
J Allergy Clin Immunol. 2018 Nov;142(5):1537-1547.e8
pubmed: 29369775
J Immunol. 2008 Jul 15;181(2):869-77
pubmed: 18606638
J Immunol. 2011 Jun 15;186(12):6815-21
pubmed: 21572032
Nat Rev Immunol. 2018 Sep;18(9):559-574
pubmed: 29967365
Annu Rev Immunol. 2010;28:573-621
pubmed: 20192811
Sci Rep. 2015 May 19;5:9743
pubmed: 25988396
Nat Immunol. 2012 Mar 18;13(5):474-80
pubmed: 22426352
J Immunol. 2008 Feb 1;180(3):1800-7
pubmed: 18209077
J Crohns Colitis. 2020 Sep 16;14(9):1190-1201
pubmed: 32100016
Immunity. 2015 Sep 15;43(3):566-78
pubmed: 26362265
J Allergy Clin Immunol. 2016 Jan;137(1):318-321.e5
pubmed: 26318071
Int Immunol. 1993 Nov;5(11):1461-71
pubmed: 7903159
Front Immunol. 2018 Mar 13;9:519
pubmed: 29593743
Nature. 2014 May 22;509(7501):497-502
pubmed: 24717441
J Exp Med. 1998 Jul 20;188(2):287-96
pubmed: 9670041
Microbiome. 2021 Feb 6;9(1):39
pubmed: 33549144
Immunity. 2002 Nov;17(5):629-38
pubmed: 12433369
Life Sci Alliance. 2019 Feb 13;2(1):
pubmed: 30760554
Nat Immunol. 2013 Nov;14(11):1146-54
pubmed: 24097110
Immunity. 2012 Sep 21;37(3):574-87
pubmed: 22981538
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Clin Invest. 2004 May;113(10):1490-7
pubmed: 15146247
Gastroenterology. 2005 Jun;128(7):1868-78
pubmed: 15940622
Annu Rev Immunol. 2007;25:297-336
pubmed: 17150027
J Vis Exp. 2019 Jan 7;(143):
pubmed: 30663692
Front Immunol. 2018 Jan 10;8:1945
pubmed: 29375569
J Exp Med. 1998 Dec 21;188(12):2205-13
pubmed: 9858507
Cells. 2019 May 28;8(6):
pubmed: 31142049
J Exp Med. 2008 Oct 27;205(11):2483-90
pubmed: 18852290
N Engl J Med. 2006 Mar 2;354(9):942-55
pubmed: 16510748
Appl Environ Microbiol. 2006 Jul;72(7):5069-72
pubmed: 16820507
Appl Environ Microbiol. 2007 Aug;73(16):5261-7
pubmed: 17586664
Nat Immunol. 2015 Jan;16(1):85-95
pubmed: 25436972
Inflamm Bowel Dis. 2006 Jun;12(6):447-56
pubmed: 16775488
Mucosal Immunol. 2009 Sep;2(5):393-402
pubmed: 19587641
Cells. 2020 May 16;9(5):
pubmed: 32429359
Nat Immunol. 2011 May;12(5):450-9
pubmed: 21460847
Gastroenterology. 2019 Dec;157(6):1584-1598
pubmed: 31513797
Adv Immunol. 2014;122:177-210
pubmed: 24507158
Trends Microbiol. 2021 Aug;29(8):700-712
pubmed: 33674141
Cell. 2014 Jan 16;156(1-2):123-33
pubmed: 24439373
Swiss Med Wkly. 2018 Sep 23;148:w14671
pubmed: 30378641
Gastroenterology. 2012 Aug;143(2):418-28
pubmed: 22522092
Nat Commun. 2018 Dec 5;9(1):5184
pubmed: 30518790
Nat Med. 2013 Jun;19(6):739-46
pubmed: 23624599
J Clin Invest. 2014 Sep;124(9):3725-40
pubmed: 25061873
Annu Rev Immunol. 2016 May 20;34:479-510
pubmed: 26927205
J Leukoc Biol. 2009 Oct;86(4):757-68
pubmed: 19465641
Gastroenterology. 2016 Dec;151(6):1100-1104
pubmed: 27693323
PLoS One. 2010 Mar 10;5(3):e9490
pubmed: 20224823
Inflamm Bowel Dis. 2017 Nov;23(11):1950-1961
pubmed: 29023267
Immunobiology. 2015 Aug;220(8):1025-9
pubmed: 25770018
Front Immunol. 2015 Aug 04;6:400
pubmed: 26300885
Cell. 2016 Jun 2;165(6):1332-1345
pubmed: 27259147
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W394-9
pubmed: 16845035
Immunity. 2011 Apr 22;34(4):554-65
pubmed: 21511184
Eur J Immunol. 2014 Feb;44(2):370-85
pubmed: 24338958
PLoS Comput Biol. 2014 Apr 03;10(4):e1003531
pubmed: 24699258
Cytokine Growth Factor Rev. 2016 Aug;30:87-93
pubmed: 26980675
Front Immunol. 2018 Sep 11;9:2082
pubmed: 30254647
Nat Rev Microbiol. 2007 Jun;5(6):405-17
pubmed: 17487145
Front Immunol. 2018 Aug 15;9:1838
pubmed: 30158927
Cell Mol Gastroenterol Hepatol. 2016 May;2(3):274-280
pubmed: 27570813
Cell Rep. 2018 Mar 13;22(11):3006-3020
pubmed: 29539427

Auteurs

Claudia Burrello (C)

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Francesco Strati (F)

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Georgia Lattanzi (G)

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy.

Angelica Diaz-Basabe (A)

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy.

Erika Mileti (E)

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Maria Rita Giuffrè (MR)

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.

Gianluca Lopez (G)

Pathology Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.

Fulvia Milena Cribiù (FM)

Pathology Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.

Elena Trombetta (E)

Clinical Chemistry and Microbiology Laboratory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Marinos Kallikourdis (M)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Laboratory of Adaptive Immunity, IRCCS Humanitas Research Hospital, Milan, Italy.

Marco Cremonesi (M)

Laboratory of Adaptive Immunity, IRCCS Humanitas Research Hospital, Milan, Italy.

Francesco Conforti (F)

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.

Fiorenzo Botti (F)

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
General and Emergency Surgery Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.

Laura Porretti (L)

Clinical Chemistry and Microbiology Laboratory Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Maria Rescigno (M)

Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Maurizio Vecchi (M)

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Massimo C Fantini (MC)

Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.

Flavio Caprioli (F)

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Federica Facciotti (F)

Department of Experimental Oncology, European Institute of Oncology IRCCS, Milan, Italy.
Department of Biotechnology and Biosciences, University of Milan-Bicocca, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH